Related Experiment Video

Updated: May 25, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

HSP90 inhibition: two-pronged exploitation of cancer dependencies

Jon Travers1, Swee Sharp, Paul Workman

  • 1Signal Transduction and Molecular Pharmacology Team, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, UK.

Drug Discovery Today
|January 17, 2012
PubMed

Insights

Inhibiting Heat Shock Protein 90 (HSP90) in cancer targets key oncoproteins and disrupts cancer cell homeostasis. This approach effectively exploits cancer

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer cells rely on Heat Shock Protein 90 (HSP90) for the stability and function of critical oncoproteins.
  • Malignant cells exhibit increased dependence on proteomic homeostasis, with HSP90 playing a central role.

Purpose of the Study:

  • To evaluate the efficacy of HSP90 inhibition in exploiting cancer-specific vulnerabilities.
  • To review the current landscape of HSP90 inhibitor discovery and development.
  • To identify strategies for enhancing the clinical effectiveness of HSP90 inhibitors.

Main Methods:

  • Review of existing clinical and preclinical data on HSP90 inhibition in cancer.
  • Analysis of the molecular mechanisms underlying HSP90 client protein dependence in cancer.
  • Assessment of the role of HSP90 in maintaining proteomic homeostasis in malignant cells.

Main Results:

  • Evidence supports that HSP90 inhibition effectively targets key oncoproteins essential for cancer cell survival.
  • HSP90 inhibition disrupts the proteomic homeostasis crucial for cancer cell proliferation and stability.
  • Current HSP90 inhibitors show promise, but clinical efficacy can be improved.

Conclusions:

  • Targeting HSP90 represents a validated strategy to simultaneously inhibit multiple oncoproteins and disrupt cancer cell homeostasis.
  • Further research and development are needed to optimize HSP90 inhibitors for improved clinical outcomes in cancer therapy.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay06:51

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...